Exceptional Response of BRAFV600E-Mutated Acinar Cell CUP to BRAF/MEK Inhibition

被引：0
|
作者：
Kerle, Irina A. [1 ,2 ,3 ,4 ,5 ]
Scheuble, Anne-Marie [6 ]
Kobitzsch, Benjamin [6 ]
Stocker, Gertraud [6 ]
Hiller, G. G. Ruth [7 ]
Badendick, Maja [8 ]
William, Doreen [5 ,9 ,10 ,11 ,12 ,13 ,14 ]
Krueger, Alexander [5 ,9 ,10 ,11 ,12 ]
Gross, Thomas [5 ,9 ,10 ,11 ,12 ]
Koegler, Anja [5 ,9 ,10 ,11 ,12 ]
Hartig, Andreas [15 ]
Richter, Daniela [1 ,2 ,3 ,4 ,16 ]
Aust, Daniela E. [15 ]
Schroeck, Evelin [5 ,9 ,10 ,11 ,12 ,13 ,14 ]
Heining, Christoph [1 ,2 ,3 ,4 ,5 ]
Glimm, Hanno [1 ,2 ,3 ,4 ,5 ,16 ]
Hacker, Ulrich T. [6 ]
机构：
[1] TUD Dresden Univ Technol, Natl Ctr Tumor Dis Dresden NCT UCC, Dept Translat Med Oncol, Dresden, Germany
[2] Helmholtz Zentrum Dresden Rossendorf HZDR, Dresden, Germany
[3] TUD Dresden Univ Technol, Fac Med, Translat Med Oncol, Dresden, Germany
[4] TUD Dresden Univ Technol, Univ Hosp Carl Gustav Carus, Dresden, Germany
[5] German Canc Consortium DKTK, Partner Site Dresden, Dresden, Germany
[6] Univ Leipzig, Univ Canc Ctr Leipzig UCCL, Canc Ctr Cent Germany CCCG, Dept Med 2,Med Ctr, Leipzig, Germany
[7] Univ Leipzig, Inst Pathol, Med Ctr, Leipzig, Germany
[8] Univ Leipzig, Dept Nucl Med, Med Ctr, Leipzig, Germany
[9] Natl Ctr Tumor Dis Dresden NCT UCC, Core Unit Mol Tumor Diagnost CMTD, Dresden, Germany
[10] German Canc Res Ctr, Heidelberg, Germany
[11] Tech Univ Dresden, Fac Med, Dresden, Germany
[12] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dresden, Germany
[13] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Inst Clin Genet, Dresden, Germany
[14] Hereditary Canc Syndrome Ctr Dresden, ERN GENTURIS, Dresden, Germany
[15] Carl Gustav Carus Univ Hosp, Inst Pathol, Dresden, Germany
[16] German Canc Res Ctr DKFZ Heidelberg, Translat Funct Canc Genom, Heidelberg, Germany
来源：
JCO PRECISION ONCOLOGY | 2024年 / 8卷
关键词：
CARCINOMA; PANCREAS; FUSIONS;
D O I：
10.1200/PO.24.00030
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：9
相关论文
共 50 条
  • [1] Successful BRAF/MEK inhibition in a patient with BRAFV600E-mutated extrapancreatic acinar cell carcinoma
    Busch, Elena
    Kreutzfeldt, Simon
    Agaimy, Abbas
    Mechtersheimer, Gunhild
    Horak, Peter
    Brors, Benedikt
    Hutter, Barbara
    Froehlich, Martina
    Uhrig, Sebastian
    Mayer, Philipp
    Schroeck, Evelin
    Stenzinger, Albrecht
    Glimm, Hanno
    Jaeger, Dirk
    Springfeld, Christoph
    Froehling, Stefan
    Zschaebitz, Stefanie
    [J]. COLD SPRING HARBOR MOLECULAR CASE STUDIES, 2020, 6 (04):
  • [2] Remarkable response of BRAFV600E-mutated metastatic pancreatic cancer to BRAF/MEK inhibition: a case report
    Li, Hong-Shuai
    Yang, Ke
    Wang, Yan
    [J]. GASTROENTEROLOGY REPORT, 2022, 10
  • [3] A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma
    Giesen, Nicola
    Chatterjee, Manik
    Scheid, Christof
    Poos, Alexandra M.
    Besemer, Britta
    Miah, Kaya
    Benner, Axel
    Becker, Nicole
    Moehler, Thomas
    Metzler, Ivana
    Khandanpour, Cyrus
    Seidel-Glaetzer, Andrea
    Trautmann-Grill, Karolin
    Kortuem, K. Martin
    Mueller-Tidow, Carsten
    Mechtersheimer, Gunhild
    Goeppert, Benjamin
    Stenzinger, Albrecht
    Weinhold, Niels
    Goldschmidt, Hartmut
    Weisel, Katja
    Raab, Marc S.
    [J]. BLOOD, 2023, 141 (14) : 1685 - 1690
  • [4] Glucocorticoid receptor antagonism overcomes resistance to BRAF inhibition in BRAFV600E-mutated metastatic melanoma
    Obrador, E.
    Estrela, J. M.
    Salvador, R.
    Marchio, P.
    Valles, S. L.
    Lopez-Blanch, R.
    Benlloch, M.
    Alcacer, J.
    Perez, C. L.
    Pellicer, J. A.
    [J]. EUROPEAN JOURNAL OF CANCER, 2020, 138 : S41 - S41
  • [5] Glucocorticoid receptor antagonism overcomes resistance to BRAF inhibition in BRAFV600E-mutated metastatic melanoma
    Estrela, Jose M.
    Salvador, Rosario
    Marchio, Patricia
    Valles, Soraya L.
    Lopez-Blanch, Rafael
    Rivera, Pilar
    Benlloch, Maria
    Alcacer, Javier
    Perez, Carlos L.
    Pellicer, Jose A.
    Obrador, Elena
    [J]. AMERICAN JOURNAL OF CANCER RESEARCH, 2019, 9 (12): : 2580 - +
  • [6] Efficacy and safety of BRAF/MEK inhibitors in BRAFV600E-mutated anaplastic thyroid cancer: a systematic review and meta-analysis
    Priantti, Jonathan N.
    Rodrigues, Natasha Maranhao Vieira
    de Moraes, Francisco Cezar Aquino
    da Costa, Allyson Guimaraes
    Jezini, Deborah Laredo
    Heckmann, Maria Izabel Ovellar
    [J]. ENDOCRINE, 2024, 86 (01) : 284 - 292
  • [7] Obesity Is Associated with BRAFV600E-Mutated Thyroid Cancer
    Rahman, Sabbir T.
    Pandeya, Nirmala
    Neale, Rachel E.
    McLeod, Donald S. A.
    Bain, Chris J.
    Baade, Peter D.
    Youl, Philippa H.
    Allison, Roger
    Leonard, Susan
    Jordan, Susan J.
    [J]. THYROID, 2020, 30 (10) : 1518 - 1527
  • [8] BRAF inhibitors in BRAFV600E-mutated pediatric high-grade gliomas: Upfront or at recurrence?
    Nobre, Liana
    Bouffet, Eric
    [J]. NEURO-ONCOLOGY, 2022, 24 (11) : 1976 - 1977
  • [9] Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600-mutated melanoma
    Amann, V. C.
    Hoffmann, D.
    Mangana, J.
    Dummer, R.
    Goldinger, S. M.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (10) : 1638 - 1640
  • [10] Sustained Response to Vemurafenib in a BRAFV600E-Mutated Anaplastic Thyroid Carcinoma Patient
    Prager, Gerald W.
    Koperek, Oskar
    Mayerhoefer, Marius E.
    Muellauer, Leonhard
    Wrba, Fritz
    Niederle, Bruno
    Zielinski, Christoph C.
    Raderer, Markus
    [J]. THYROID, 2016, 26 (10) : 1515 - 1516
12345